Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Gynecologic Oncology
Journal
Overview
Identity
Overview
Publication Venue For
International gynecologic cancer society (IGCS) 2021 meeting report
. 164:208-211.
2022
Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance
. 164:170-180.
2022
Corrigendum to ʻA state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States’ (Gynecologic Oncology (2020) 159(2) (344–353), (S0090825820338506), (10.1016/j.ygyno.2020.08.033))
. 163:614.
2021
Corrigendum to “Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis” (Gynecologic Oncology (2021) 162(3) (532–538), (S0090825821005114), (10.1016/j.ygyno.2021.06.017))
. 163:616-617.
2021
Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study
. 163:85-92.
2021
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis
. 162:532-538.
2021
It's time to re-evaluate cervical Cancer screening after age 65
. 162:200-202.
2021
Understanding the effect of mechanical forces on ovarian cancer progression
. 162:154-162.
2021
Erratum to “A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States” (Gynecologic Oncology (2020) 159(2) (344–353), (S0090825820338506), (10.1016/j.ygyno.2020.08.033))
. 161:913.
2021
Standing on the shoulders of giants: Mentorship advice from leaders in the field
. 161:339-341.
2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer
. 161:496-501.
2021
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations
. 160:817-826.
2021
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II
. 160:827-834.
2021
The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
. 160:800-804.
2021
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients
. 160:793-799.
2021
Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy
. 160:285-294.
2021
Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm
. 159:773-777.
2020
A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States
. 159:344-353.
2020
51st Annual Meeting of the Society of Gynecologic Oncology
. 159:1.
2020
Corrigendum to ‘Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer’ [Gynecologic Oncology 157 (2020) 765–774] (Gynecologic Oncology (2020) 157(3) (765–774), (S0090825820302262), (10.1016/j.ygyno.2020.03.010))
. 159:295.
2020
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
. 158:562-569.
2020
Risk of second primary cancers among survivors of gynecological cancers
. 158:719-726.
2020
Human papillomavirus: The other invisible enemy
. 158:254-255.
2020
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic
. 158:236-243.
2020
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis
. 158:16-24.
2020
Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES)
. 158:123-129.
2020
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II
. 158:201-207.
2020
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I
. 158:194-200.
2020
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
. 157:578-584.
2020
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
. 157:765-774.
2020
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
. 157:161-166.
2020
The Society of Gynecologic Oncology wellness curriculum pilot: A groundbreaking initiative for fellowship training
. 156:710-714.
2020
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
. 156:301-307.
2020
Extensive financial hardship among gynecologic cancer patients starting a new line of therapy
. 156:271-277.
2020
Human papillomavirus vaccination: Ongoing challenges and future directions
. 156:498-502.
2020
Reducing emergency department (ED) computed tomography (CT) utilization in women treated for gynecologic cancers
. 156:288-292.
2020
The financial impact of an enhanced recovery after surgery (ERAS) protocol in an academic gynecologic oncology practice
. 156:284-287.
2020
Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models
2020
Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation
. 155:365-373.
2019
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer
. 155:201-206.
2019
Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012))
. 154:449.
2019
Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic
. 154:379-382.
2019
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
. 154:110-117.
2019
The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
. 153:521-529.
2019
Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution
. 153:242-247.
2019
Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
. 153:381-384.
2019
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer
. 152:445-451.
2019
The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction
. 152:127-132.
2019
Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
. 151:501-505.
2018
Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy
. 151:282-286.
2018
Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
. 151:4-5.
2018
Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman
. 151:6-9.
2018
Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey
. 150:494-500.
2018
Endometrial cancer: Molecular markers and management of advanced stage disease
. 150:569-580.
2018
Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years
. 150:391-397.
2018
Financial toxicity – An overlooked side effect
. 150:3-6.
2018
Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication
. 149:506-512.
2018
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study
. 149:525-530.
2018
Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic
. 149:337-340.
2018
Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
. 149:49-52.
2018
HPV vaccination
. 148:3-4.
2018
Values and worries of ovarian cancer patients
. 147:433-438.
2017
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study
. 147:98-103.
2017
The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis
. 146:642-646.
2017
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study
. 145:291-297.
2017
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort
. 144:274-278.
2017
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
. 144:125-129.
2017
Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial
. 144:193-199.
2017
Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service
. 143:105-108.
2016
Ovarian cancer and the immune system — The role of targeted therapies
. 142:349-356.
2016
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
. 142:25-29.
2016
A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results
. 141:364-370.
2016
A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3)
. 140:245-252.
2016
Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?
. 143:617-621.
2016
Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review
. 143:674-683.
2016
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study
. 140:264-269.
2016
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients
. 139:413-418.
2015
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
. 139:59-62.
2015
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma
. 138:656-662.
2015
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
. 138:689-693.
2015
Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian cancers: An observational study ancillary analysis
. 138:267-271.
2015
Ovarian and cervical cancer patient derived xenografts: The past, present, and future
. 138:486-491.
2015
A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer
. 136:293-299.
2015
Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance
. 136:178-182.
2015
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?
. 136:43-47.
2015
Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial
. 137:47-54.
2015
Functional variants in CYP1A1 and GSTM1 are associated with clearance of cervical HPV infection
. 135:560-564.
2014
Teaching gynecologic oncology in Low resource settings: A collaboration of health volunteers overseas and the society of gynecologic oncology
. 135:580-582.
2014
Diabetes mellitus and ovarian cancer: More complex than just increasing risk
. 135:273-277.
2014
Abnormal CA-125 levels in menopausal women without ovarian cancer
. 135:34-37.
2014
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study
. 133:433-438.
2014
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy
. 132:531-536.
2014
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
. 134:331-337.
2014
Black race independently predicts worse survival in uterine carcinosarcoma
. 133:238-241.
2014
Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients
. 132:227-230.
2014
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
. 134:112-120.
2014
Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96
. 132:203-210.
2014
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma
. 133:234-237.
2014
Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center
. 133:142-146.
2014
Validation of a venous thromboembolism risk assessment model in gynecologic oncology
. 134:160-163.
2014
Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.
. 131:508-511.
2013
The Wnt/β-catenin pathway in ovarian cancer: A review
. 131:772-779.
2013
Erratum: HPV vaccination in women treated for CIN2/3: It's still all about prevention (Gynecologic Oncology (2013) 130 (255-256))
. 131:499.
2013
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer
. 131:493-498.
2013
A phase i clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
. 130:518-524.
2013
Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer
. 130:421-425.
2013
Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis
. 130:416-420.
2013
Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?
. 130:317-322.
2013
HPV vaccination in women treated for CIN2/3: It's still all about prevention
. 130:255-256.
2013
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins
. 129:528-532.
2013
Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials
. 129:251-257.
2013
Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors
. 131:59-62.
2013
Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility
. 131:158-162.
2013
Re: "The utilization of palliative care in gynecologic oncology patients near the end of life".
. 127:678-679.
2012
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer
. 127:420-425.
2012
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix
. 127:267-272.
2012
The utilization of palliative care in gynecologic oncology patients near the end of life.
. 127:175-179.
2012
Management of complex pelvic masses using a multivariate index assay: A decision analysis
. 126:364-368.
2012
Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy
. 126:69-72.
2012
Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion
. 125:646-648.
2012
The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells
. 125:226-230.
2012
Does economic burden influence quality of life in breast cancer survivors?
. 124:437-443.
2012
Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells
. 124:598-605.
2012
Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study
. 123:360-364.
2011
Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies
. 123:54-57.
2011
A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma
. 122:604-607.
2011
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer
. 122:532-535.
2011
Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines
. 122:396-401.
2011
Erratum: Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions (Gynecologic Oncology (2010) 118 (274-277))
. 121:643.
2011
Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation
. 121:637-638.
2011
Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model
. 121:193-199.
2011
Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence
. 122:501-504.
2011
Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening
. 119:237-242.
2010
Long-term outcome and natural history of uterine adenosarcomas
. 119:305-308.
2010
Overcoming TRAIL resistance in ovarian carcinoma
. 119:157-163.
2010
Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions
. 118:274-277.
2010
Evaluation of EVI1 and EVI1s (Δ324) as potential therapeutic targets in ovarian cancer
. 118:189-195.
2010
Overcoming the barriers to HPV vaccination in high-risk populations in the US
. 117:486-490.
2010
What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?
. 117:481-485.
2010
Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus
. 117:248-254.
2010
Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy
. 117:387-388.
2010
How does public policy impact cervical screening and vaccination strategies?
. 119:175-180.
2010
Extragenital adenosarcoma: A case report, review of the literature, and management discussion
. 115:472-475.
2009
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
. 115:244-248.
2009
The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
. 114:424-426.
2009
The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer
. 114:242-245.
2009
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
. 113:384-390.
2009
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
. 112:558-562.
2009
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
. 112:601-604.
2009
The effect of obesity on survival in patients with ovarian cancer
. 112:389-393.
2009
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer
. 111:89-94.
2008
Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001)
. 110:270.
2008
Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer
. 110:268-269.
2008
Age considerations when vaccinating against HPV
. 109.
2008
Initial lessons learned in HPV vaccination
. 109.
2008
The disparity of cervical cancer in diverse populations
. 109.
2008
The future of vaccines for cervical cancer
. 109.
2008
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model
. 108:591-597.
2008
Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancer
. 108:166-172.
2008
The current and future role of screening in the era of HPV vaccination
. 109.
2008
Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
. 107:398-403.
2007
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers
. 106:614-621.
2007
Complete uterine necrosis following chemoradiation for advanced cervical cancer: A case report
. 106:265-267.
2007
A multi-institutional review of outcomes of endometrial stromal sarcoma
. 105:630-634.
2007
Fertility-sparing radical abdominal trachelectomy for clear cell adenocarcinoma of the upper vagina: A case report
. 105:820-822.
2007
Anemia correction in malignancy management: Threat or opportunity?
. 105:517-529.
2007
Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model
. 105:291-298.
2007
A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer
. 105:223-227.
2007
Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd)
. 105:113-121.
2007
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy
. 104:591-595.
2007
Primary appendiceal cancer: Gynecologic manifestations and treatment options
. 104:602-606.
2007
Fertility sparing therapy in a patient with placental site trophoblastic tumor: A case report
. 103:1141-1143.
2006
Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy
. 103:985-989.
2006
Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision
. 103:749-751.
2006
Unilateral cervical cancer in a patient with cervix duplex
. 103:346-348.
2006
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer
. 102:338-342.
2006
Recurrent basosquamous cell carcinoma of the vulva
. 102:400-402.
2006
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
. 101:46-54.
2006
Carcinosarcoma of the ovary - A case series
. 100:128-132.
2006
Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters)
. 100:219-220.
2006
Optical detection of cervical neoplasia: results from an internally-controlled multicenter study.
. 99:S53.
2005
The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)
. 99:557-563.
2005
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base
. 99:530-535.
2005
A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses
. 99:443-446.
2005
Predictors of outcomes for women with cervical carcinoma
. 99:432-436.
2005
Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent
. 98:376-382.
2005
Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies.
. 98:490-492.
2005
Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report
. 98:155-157.
2005
Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery
. 96:341-348.
2005
Immune responses to human papillomavirus in genital tract of women with cervical cancer
. 96:452-461.
2005
A case report of rhabdomyosarcoma of the uterus associated with uterine inversion
. 96:850-853.
2005
Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis
. 97:387-394.
2005
Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy
. 97:713-715.
2005
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy
. 98:309-312.
2005
The impact of aborted radical hysterectomy in patients with cervical carcinoma
. 95:204-207.
2004
Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma
. 94:352-362.
2004
Primary lung large cell carcinoma metastatic to the vulva: A case report and review of the literature
. 94:829-831.
2004
Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer
. 93:429-434.
2004
The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy
. 92:215-219.
2004
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation
. 89:233-235.
2003
Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy
. 89:295-300.
2003
Complications of indwelling venous access devices in patients with gynecologic malignancies
. 91:591-595.
2003
Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy
. 91:470-475.
2003
A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis
. 87:57-63.
2002
Conservative management of Stage I endometrial carcinoma after surgical staging
. 84:194-200.
2002
Treatment preferences in recurrent ovarian cancer
. 86:200-211.
2002
A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts
. 83:432-438.
2001
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites
. 82:57-63.
2001
Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix
. 83:370-377.
2001
Genetic origin of malignant trophoblastic neoplasms analyzed by sequence tag site polymorphic markers
. 81:247-253.
2001
Immunohistochemical expression of molecular markers in an avian model: A potential model for preclinical evaluation of agents for ovarian cancer chemoprevention
. 81:373-379.
2001
Predictors of outcome in small cell carcinoma of the cervix - A case series
. 83:216-220.
2001
Transcriptional targeting for ovarian cancer gene therapy
. 82:229-237.
2001
A patient presenting with a pelvic mass, elevated CA-125, and fever
. 77:471-472.
2000
An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
. 74:227-234.
1999
High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type I vector
. 71:278-287.
1998
An umbilical metastasis after laparoscopy for squamous cell carcinoma of the cervix
. 64:507-509.
1997
Intraperitoneal radioimmunotherapy of ovarian cancer with
177
Lu- CC49: A phase I/II study
. 65:94-101.
1997
Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy
. 64:378-385.
1997
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbb-2 single-chain antibody
. 59:8-14.
1995
Intracranial metastases from carcinoma cervix and review of literature
. 46:391-392.
1992
Coexisting intraductal breast carcinoma and metastatic choriocarcinoma presenting as a breast mass
. 43:295-299.
1991
Establishment and characterization of a human cell line from a serous papillary endometrial carcinoma
. 33:301-312.
1989
Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits
. 32:314-318.
1989
Endometrial stromal cells in culture: An attempt to understand the genesis and biologic activity of uterine sarcomas
. 24:247-257.
1986
Genital aerobic bacterial flora of women receiving radiotherapy for gynecologic malignancy
. 23:35-39.
1986
An extra-adrenal pheochromocytoma mimicking lymph node metastasis from a cervical cancer
. 13:416-422.
1982
Identity
International Standard Serial Number (issn)
0090-8258
Electronic International Standard Serial Number (eissn)
1095-6859